{
  "Clinical Information": [],
  "Patent Information": [],
  "Sequence Information": {
    "ID": "AP05236",
    "Peptide Name": "Pleurocidin-VA (Synthetic AMPs, V to A analog, UCLL1)",
    "Source": "amino acid substitution, amphibians, animal-derived, natural derivatives",
    "Family": "Not found",
    "Gene": "Not found",
    "Sequence": "GWGSFFKKAAHAGKHAGKAALTHYL",
    "Sequence Length": 25,
    "UniProt Entry": "Ref",
    "Protein Existence": "Not found",
    "Biological Activity": [
      "Anti-Gram+",
      "Gram-",
      "Anti-MRSA"
    ],
    "Target Organism": "Not found",
    "Hemolytic Activity": "Not found",
    "Cytotoxicity": "Not found",
    "Binding Target": "Not found",
    "Linear/Cyclic": "Not found",
    "N-terminal Modification": "Not found",
    "C-terminal Modification": "Not found",
    "Nonterminal Modifications and Unusual Amino Acids": "Not found",
    "Stereochemistry": "Not found",
    "Structure": "Helix",
    "Structure Description": "Not found",
    "Helical Wheel Diagram": "Not found",
    "PDB ID": "",
    "Predicted Structure": "Not found",
    "Formula": "Not found",
    "Absent Amino Acids": "Not found",
    "Common Amino Acids": "Not found",
    "Mass": "Not found",
    "PI": "Not found",
    "Basic Residues": "Not found",
    "Acidic Residues": "Not found",
    "Hydrophobic Residues": "Not found",
    "Net charge": 7,
    "Boman Index": 0.38,
    "Hydrophobicity": "Not found",
    "Aliphatic Index": "Not found",
    "Half Life": "Not found",
    "Extinction Coefficient Cystines": "Not found",
    "Absorbance 280nm": "Not found",
    "Polar Residues": "Not found",
    "Function": "Not found",
    "Hydrophobic residue%": "44%",
    "Crucial residues": ""
  },
  "Literature Information": {
    "Literature": "Sequence analysis: APD analysis reveals that this sequence is similar (92%) toPleurocidinA=G=R: 16%; H: 12%.  Four K residues were replaced with four R.Activity:  Active against Gram- K. pneumoniae NCTC 13368 or M6 (MIC 4-8 ug/ml),  A. baumannii AYE or ATCC 17978 (MIC 1-2 ug/ml), P. aeruginosa NCTC 13437 or PAO1 (MIC 16-32 ug/ml), E. coli NCTC 12923 (MIC 1 ug/ml), Gram+ methicillin-sensitive S. aureus ATCC 9144 (MIC 8 ug/ml), S. aureus MRSA NCTC 13616 or MRSA NCTC 13277 (MIC 64-128 ug/ml), vancomycin-sensitive and resistant E. faecalis NCTC 775 or NCTC 12204 (MIC 32-128 ug/ml) (anti-VRE).Peptide engineering: D-form has an activity spectrum similar to the L-form (D=L).Structure:  random coil in buffer and helical in SDS or POPG or POPE/POPG lipids.",
    "Author": "Manzo G, Hind CK, Ferguson PM, Amison RT, Hodgson-Casson AC, Ciazynska KA, Weller BJ, Clarke M, Lam C, Man RCH, Shaughnessy BGO, Clifford M, Bui TT, Drake AF, Atkinson RA, Lam JKW, Pitchford SC, Page CP, Phoenix DA, Lorenz CD, Sutton JM, Mason AJ.2020",
    "Reference": "Commun Biol. 2020 Nov 27;3(1):697. doi: 10.1038/s42003-020-01420-3.PubMed",
    "Title": "A pleurocidin analogue with greater conformational flexibility, enhanced antimicrobial potency and in vivo therapeutic efficacy."
  },
  "3D Structure": []
}